Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 759-765

  Kitko, Carrie L ^a   Paczesny, Sophie ^b   Yanik, Gregory ^a   Braun, Thomas ^c   Jones, Dawn ^b   Whitfield, Joel ^b   Choi, Sung W ^a   Hutchinson, Raymond J ^a   Ferrara, James L M ^a   Levine, John E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

GVHD; Hematopoietic stem cell transplantation; Pediatrics; TNF

Indexed keywords

ACICLOVIR; BIOLOGICAL MARKER; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUCONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VORICONAZOLE;

ACCURACY; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MYCOSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; UNITED STATES; WHOLE BODY RADIATION;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 44649181014     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.002     Document Type: Article

References (38)

1. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 (1990) 1464-1472
2. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8 (2002) 387-394
3. Wojnar J., Giebel S., Holowiecka-Goral A., et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant 11 (2006) 14-20
4. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
5. Petersdorf E.W. Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol 18 (2006) 559-564
6. Weisdorf D.J., McGlave P.B., Ramsay N.K., et al. Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children. Br J Haematol 69 (1988) 351-358
7. McGlave P.B., Haake R., Miller W., Kim T., Kersey J., and Ramsay N.K. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood 70 (1987) 1325-1330
8. Locatelli F., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105 (2005) 410-419
9. Kennedy-Nasser A.A., Leung K.S., Mahajan A., et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 12 (2006) 1277-1284
10. Giebel S., Giorgiani G., Martinetti M., et al. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant 31 (2003) 987-993
11. Sedlacek P., Formankova R., Keslova P., et al. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin. Bone Marrow Transplant 38 (2006) 745-750
12. Gassas A., Sung L., Saunders E.F., and Doyle J.J. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant 38 (2006) 739-743
13. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
14. Ferrara J.L., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
15. Piguet P.F., Grau G.E., Allet B., and Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166 (1987) 1280-1289
16. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
17. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., and Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
18. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 102 (1998) 1882-1891
19. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
20. Schmaltz C., Alpdogan O., Muriglan S.J., et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101 (2003) 2440-2445
21. Borsotti C., Franklin A.R.K., Lu S.X., et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 110 (2007) 783-786
22. Hill G., Teshima T., Gerbitz A., et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest 104 (1999) 459-467
23. Holler E., Kolb H.J., Mittermuller J., et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86 (1995) 890-899
24. Herve P., Flesch M., Tiberghien P., et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79 (1992) 3362-3368
25. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
26. Levine J., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute GVHD. Blood 111 (2008) 2470-2475
27. Busca A.A., Locatelli F.F., Marmont F.F., Ceretto C.C., and Falda M.M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 82 (2007) 45-52
28. Holler E., Kolb H.J., Hintermeier-Knabe R., et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25 (1993) 1234-1236
29. Hintermeier-Knabe R., Brockhaus M., Holler E., et al. Sequential release of tumor necrosis factor alpha and tumor necrosis factor receptors in complications of human bone marrow transplantation. In: Freund M., Link H., Schmidt R., and Welte K. (Eds). Cytokines in Hemopoiesis, Oncology, and AIDS II (1992), Springer-Verlag, Berlin 443-448
30. Vandenabeele P., Declercq W., Beyaert R., and Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5 (1995) 392-399
31. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
32. Lee K.H., Choi S.J., Lee J.H., et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 90 (2005) 939-948
33. Kebriaei P., Kline J., Stock W., et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 35 (2005) 965-970
34. Song K.W., and Lipton J.J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 36 (2005) 183-191
35. Lee S., Cho B., Kim S., et al. Allogeneic stem cell transplantation in first complete remission enhances graft-vs.-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-vs.-host disease. Biol Blood Marrow Transplant 13 (2007) 1083-1094
36. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 108-114
37. Al-Ali H.K., Brand R., van Biezen A., et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21 (2007) 1945-1951
38. Beilhack A., Schulz S., Baker J., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106 (2005) 1113-1122